Prescription Trends and Clinical Decision‐Making in Neuropathic Pain Pharmacological Treatment: Results From a Cross‐Sectional Survey by the Spanish Pain Society

TL;DR

A survey of Spanish pain specialists reveals inconsistent adherence to guidelines in treating neuropathic pain, with a strong reliance on personal experience and common use of gabapentinoids and antidepressants.

Contribution

This is the first systematic assessment of neuropathic pain management practices in Spain, highlighting variability and the need for national consensus.

Findings

Gabapentinoids and tricyclic antidepressants are the most commonly prescribed first-line treatments for neuropathic pain.

Tramadol is frequently used as a second-line treatment despite conflicting guidelines.

Half of the participants reported managing drug tolerance through dose escalation or switching drug classes.

Abstract

Neuropathic pain (NP) is a complex chronic condition with limited therapeutic effectiveness. Despite multiple drug classes and international guidelines, real‐world adherence remains inconsistent, and data on prescribing practices among pain specialists is scarce.

We conducted a nationwide cross‐sectional survey among members of the Spanish Pain Society in May 2025. A structured 62‐item questionnaire assessed prescribing habits, decision‐making criteria, guideline adherence, dosage patterns, and the recognition and management of tolerance. Sociodemographic and professional data were also collected.

A total of 220 pain specialists (52% female) completed the survey; 28% had over 20 years of clinical experience. Satisfaction with current pharmacological options was modest, with 52% reporting dissatisfaction or indifference. Prescribing was mainly guided by clinical experience (43%) and guideline recommendations (36%). Gabapentin (45%) and pregabalin (40%) were the most frequent first‐line choices, followed by tricyclic antidepressants (amitriptyline; 9%), duloxetine (5%) and venlafaxine (1%). Tramadol dominated second‐line use (65%), followed by capsaicin (22%) or lidocaine (5%) patches. Half of the participants reported tolerance, typically after 3–12 months, managed mainly by dose escalation or switching drug classes. Dosage practices for gabapentinoids and antidepressants showed marked heterogeneity, with frequent deviations from recommended titration protocols.

NP management in Spain shows variability and partial alignment with international guidelines. Gabapentinoids, tricyclic antidepressants and duloxetine remain preferred treatments, but reliance on personal experience and awareness of tolerance hinder evidence‐based practice. Quantifying Spanish pain specialists' views on tolerance supports calls for national consensus, better dosing education and further research to harmonise care and improve outcomes.

This nationwide survey provides the first systematic assessment of neuropathic pain management in Spain, revealing marked variability, only partial adherence to international guidelines, and persistent reliance on clinical experience over evidence. It confirms gabapentinoids, tricyclic antidepressants and duloxetine as preferred treatments, identifies continued tramadol use despite conflicting recommendations, and quantifies for the first time clinicians' perception and management of tolerance. These findings fill a major evidence gap and directly inform future national consensus, educational initiatives and clinical practice improvement.

Figures